Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high3,335.75 20/03/17
52 week low1,612.50 28/04/16
52 week change 1,095.00 (57.48%)
4 week volume437,984 26/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Chi-Med chief scientific officer joins board

Hutchison China MediTech has appointed Dr Weiguo Su as an executive director and member of the technical committee...

Appointment of Director

RNS Number: 4316A Hutchison China Meditech Limited 24 March 2017 Appointment of Director London: Friday, March 24 , 2017: Hutchison China MediTech Limited ("Chi-Med")or the ("Company") (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as E xecutive Director and member of Technical Committee with effect from March 27...

Chi-Med to host R&D Briefings

RNS Number: 0625A Hutchison China Meditech Limited 21 March 2017 Press Release Chi-Med to host R&D Briefings on March 29 & 30, 2017 London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an o...

Director Deals - Hutchison China Meditech Ltd (HCM)

Paul Carter, Non Executive Director, bought 2,800 shares in the company on the 15th March 2017 at a price of 2637.00p. Th...

Directors' Share Dealing

RNS Number: 9126Z Hutchison China Meditech Limited 20 March 2017 Directors' Share Dealing London: Monday, March 20 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in the capital of Ch...

Grant of Awards under Long Term Incentive Plan

RNS Number: 6898Z Hutchison China Meditech Limited 16 March 2017 Press release Grant of Awards under Long Term Incentive Plan London: Thursday , March 1 6 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 15, 2017 , it granted conditional awards ("LTIP Awards") under the Long Term Incentive Plan ("L...

Hutchison China MediTech shares tipped to hit record high

There are high hopes for Chi-Med's big cancer drug and City experts say the shares are undervalued. Graeme Evans report...

Higher commodity prices boost FTSE as May considers triggering Article 50

Takeover activity among mid-cap stocks dominated the market on Monday, while speculation grew that UK Prime Minist...

Equity Research (HCM)

edison investment research
Hutchison China MediTech Limited
06/03/2017
Hutchison (HCM) and partner Lilly announced positive, top-line pivotal phase III trial results for fruquintinib in 3rd line colorectal cancer. The China based FRESCO study evaluating 416 patients who...
edison investment research
Hutchison China MediTech Limited
27/02/2017
Hutchison (HCM) and partner AstraZeneca presented positive preliminary data from the ongoing phase II proof-of-concept trial evaluating savolitinib (c-Met TKI) in papillary renal cell carcinoma (PRCC...
Hutchison China MediTech Ltd.
03/08/2016
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...

Latest discussion posts More

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'26%
NATIONAL GRID23%
BP20%
LLOYDS GRP.19%
GLAXOSMITHKLINE18%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM